ABSTRACT
While promising, convalescent plasma remains experimental and is not proven effective for COVID-19. In addition, many questions remain regarding the accuracy and predictive value of antibody testing of donors and patients, optimal donor selection, optimal timing, and selection of patients most likely to benefit. Until these questions are answered, convalescent plasma should ideally be used in the context of well-designed clinical trials.
Footnotes
The authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.
- Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.
- Simon R. Mucha, MD
- NurJehan Quraishy, MD⇑
- Section Head Transfusion Medicine, Department of Clinical Pathology, Cleveland Clinic; Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
- Address:
NurJehan Quraishy, MD, Clinical Pathology, Q6-2, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; quraisn{at}ccf.org
ABSTRACT
While promising, convalescent plasma remains experimental and is not proven effective for COVID-19. In addition, many questions remain regarding the accuracy and predictive value of antibody testing of donors and patients, optimal donor selection, optimal timing, and selection of patients most likely to benefit. Until these questions are answered, convalescent plasma should ideally be used in the context of well-designed clinical trials.
Footnotes
The authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.
- Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.